Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eli Lilly and Company
Scientific Title
A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy